Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 8/2017

Open Access 01-08-2017 | Review

Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications

Authors: Michael Philbin, John Niewoehner, George J. Wan

Published in: Advances in Therapy | Issue 8/2017

Login to get access

Abstract

Introduction

Repository corticotropin injection (RCI; H.P. Acthar® Gel; Mallinckrodt Pharmaceuticals Inc., Hampton, NJ) is a highly purified, prolonged-release porcine preparation of adrenocorticotropic hormone (ACTH) analogue that is FDA-approved for treatment of 19 autoimmune and inflammatory disorders. The diverse physiological actions of RCI at the melanocortin receptors (MCRs) affect processes involved in inflammation, pigmentation, steroidogenesis, and immunomodulation. Although RCI has been approved to treat inflammatory and autoimmune diseases for more than 60 years, recent progress in understanding both MCRs and the effects of RCI in modulating immune responses has led to increased interest in RCI as a therapeutic choice. The objective of this narrative literature review is to summarize key clinical and economic data on RCI treatment of seven disorders: infantile spasms (IS), multiple sclerosis (MS) relapses, proteinuria in nephrotic syndrome, rheumatoid arthritis (RA), dermatomyositis/polymyositis (DM/PM), systemic lupus erythematosus (SLE), and symptomatic sarcoidosis based on published literature and product information. An extended report is available as the Academy of Managed Care Pharmacy (AMCP) Formulary dossier for H.P. Acthar® Gel.

Methods

Key studies of clinical efficacy and healthcare utilization and cost from 1956 to 2016 are summarized.

Results

The evidence supports the efficacy of RCI across the seven indications. RCI is effective as a first-line therapy for IS. For the other six conditions, RCI may improve clinical outcomes during exacerbations or when the condition is resistant to conventional treatments. Use of RCI is associated with reduced use of biologics, corticosteroids, and disease-modifying antirheumatic drugs. Initiation of RCI therapy in patients with IS, MS, RA, SLE, or DM/PM has been associated with lower post-therapy healthcare utilization and medical costs, including decreases in hospitalizations, hospital length of stay, outpatient visits, and emergency department visits.

Conclusion

The evidence suggests that RCI may improve inflammatory and autoimmune disease control and patient quality of life, particularly in complex patients, and yield healthcare cost savings that demonstrate the medicine’s value.

Funding

Mallinckrodt Pharmaceuticals Inc.
Appendix
Available only for authorised users
Literature
1.
H.P. Acthar Gel (repository corticotropin injection) [prescribing information]. Hazelwood: Mallinckrodt ARD, Inc.; 2015.
2.
Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Ther Adv Neurol Disord. 2014;7(2):83–96.CrossRefPubMedPubMedCentral
3.
4.
American Academy of Managed Care Pharmacy (AMCP) Dossier, H.P. Acthar® Gel (repository corticotropin injection). St. Louis: Mallinckrodt Pharmaceuticals, Inc.; 2016.
5.
Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668–81.CrossRefPubMedPubMedCentral
6.
Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–80.CrossRefPubMedPubMedCentral
7.
Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51(10):2175–89.CrossRefPubMed
8.
9.
An S, Nagarajan E, Sánchez Fernández I, et al. Time elapsed from onset of infantile spasms to diagnosis and treatment. Epilepsy Curr. 2015;15(Suppl 1):198–9.
10.
Watemberg N. Infantile spasms: treatment challenges. Curr Treat Options Neurol. 2012;14(4):322–31.CrossRefPubMed
11.
12.
Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996;97(3):375–9.PubMedPubMedCentral
13.
Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016;79(3):475–84.CrossRefPubMed
14.
Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr. 1994;124(5 Pt 1):803–6.CrossRefPubMed
15.
Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983;103(4):641–5.CrossRefPubMed
16.
Hrachovy RA, Frost JD Jr, Kellaway P, Zion T. A controlled study of ACTH therapy in infantile spasms. Epilepsia. 1980;21(6):631–6.CrossRefPubMed
17.
18.
Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545–59.CrossRefPubMed
19.
Gettig J, Cummings JP, Matuszewski KHP. Acthar Gel and cosyntropin review: clinical and financial implications. P T. 2009;34(5):250–7.PubMedPubMedCentral
20.
Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo–final report. Neurology. 1970;20(5):1–59.PubMed
21.
Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381–9.CrossRefPubMedPubMedCentral
22.
23.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300.CrossRefPubMedPubMedCentral
24.
Keddis MT, Karnath BM. The nephrotic syndrome. Hosp Physician. 2007;38:25–30.
25.
Gkrouzman E, Kirou KA, Seshan SV, Chevalier JM. Minimal change disease as a secondary and reversible event of a renal transplant case with systemic lupus erythematosus. Case Rep Nephrol. 2015;2015:987212.PubMedPubMedCentral
26.
27.
Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58–67.CrossRefPubMed
28.
Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011;5:147–53.CrossRefPubMedPubMedCentral
29.
30.
Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transpl. 2014;29(8):1570–7.CrossRef
31.
Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17(1):37.CrossRefPubMedPubMedCentral
32.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.CrossRefPubMed
33.
Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014;43(4):479–88.CrossRefPubMed
34.
Gaylis N, Needell S, Sagliani J. The effect of adrenocorticotropin gel (HP Acthar Gel) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective. Ann Rheum Dis. 2015;74(Suppl 2):1066–7.CrossRef
35.
Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action. Ann Rheum Dis. 2015;74(Suppl 2):1066.CrossRef
36.
Alexanderson H, Lundberg IE. Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. Clin Exp Rheumatol. 2007;25(6 Suppl 47):153–8.PubMed
37.
Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;8:Cd003643.
38.
Dimachkie MM, Barohn RJ. Idiopathic inflammatory myopathies. Front Neurol Neurosci. 2009;26:126–46.CrossRefPubMed
39.
Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Dev Ther. 2012;6:133–9.CrossRef
40.
Aggarwal RM, Marder G, Loganathan P, et al. Efficacy and safety of adrenocorticotropic hormone gel (Acthar Gel®) in refractory dermatomyositis or polymyositis. Abstract presented at American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting [abstract no. 2363]; November 6–11, 2015; San Francisco.
41.
Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(10):781–9.CrossRefPubMedPubMedCentral
42.
43.
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999;42(9):1785–1796.
44.
Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905–12.CrossRefPubMedPubMedCentral
45.
Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3(1):e000180.CrossRefPubMedPubMedCentral
46.
47.
Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–81.CrossRefPubMed
48.
49.
Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Dev Ther. 2013;7:325–38.
50.
O’Regan A, Berman JS. Sarcoidosis. Ann Intern Med. 2012;156(9):ITC5-1-15.
51.
Salomon A, Appel B, Collins SF, Herschfus JA, Segal MS. Sarcoidosis: pulmonary and skin studies before and after ACTH and cortisone therapy. Dis Chest. 1956;29(3):277–91.CrossRefPubMed
52.
Baughman RP, Barney JB, O’Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.CrossRefPubMed
53.
Gold LS, Schepman PB, Wang WJ, et al. Healthcare costs and resource utilization in patients with infantile spasms treated with H.P. Acthar Gel®. Adv Ther. 2016;33(8):1293–304.CrossRefPubMedPubMedCentral
54.
Gold LS, Suh K, Schepman PB, Damal K, Hansen RN. Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel®. Adv Ther. 2016;33(8):1279–92.CrossRefPubMedPubMedCentral
55.
Wu B, Deshpande G, Popelar B, Wan G, Philbin M. Real-world treatment patterns and demographic, clinical and economic characteristics of rheumatoid arthritis patients initiating repository corticotropin injection therapy. American Society of Health-System Pharmacists Summer Meeting; Jun 11–15, 2016; Baltimore.
56.
Knight T, Bond C, Popelar B, Wang L, Philbin M. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. American Society of Health-System Pharmacists Summer Meeting; Jun 11–15, 2016; Baltimore.
57.
Wu B, Deshpande G, Tunceli O, et al. Real-world treatment patterns and demographic, clinical, and economic characteristics of systemic lupus erythematosus (SLE) patients initiating repository corticotropin injection therapy. AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016; April 19–22, 2016; San Francisco.
58.
Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. American College of Rheumatology Annual Meeting; May 15–19, 2016; Washington.
Metadata
Title
Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications
Authors
Michael Philbin
John Niewoehner
George J. Wan
Publication date
01-08-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 8/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0569-9

Other articles of this Issue 8/2017

Advances in Therapy 8/2017 Go to the issue

Review

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Original Research

Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study

Original Research

Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial

Original Research

Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation

Original Research

Intracameral Dexamethasone Injection as Adjuvant Therapy in Endothelial Immune Reaction After Penetrating and Posterior Lamellar Keratoplasty: A Retrospective Clinical Observation

Original Research

Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits